MK-2866 (Ostarine) Review | Buy Liquid Ostarine

Please Read our Disclaimer

Ostarine also known as MK-2866, enobosarm and GTx-024 is a compound that is a selective androgen receptor modulator (SARM). It was developed by GTx INC pharmaceutical company based in Memphis.
Research is being carried out on ostarine to learn more of its ability to prevent muscle loss, muscle wasting, and dystrophy.

Although ostarine and other SARMs are not yet approved for use by humans, they generate growing interest medically because they might be a future means of effectively treating various health conditions.

These conditions are often the result of cancer and can have disastrous consequences on a person’s life. The trials conducted on animal subjects so far indicate that this SARM is highly effective in combating the conditions.

This MK-2866 review tells you all you need to know about this compound.

Brief MK-2866 Review

There has been tremendous media hype around SARMs lately. This has inadvertently led to widespread confusion on the subject. Mk-2866 is one of the most popular SARMS and many people are curious on the subject.

This article will show everything you need to know about Ostarine with the hopes of clearing your confusion and making you knowledgeable on the subject. At the end of the article you’ll also find out where to buy ostarine.

SARM compounds aren’t new, they have been in circulation for quite a few years now and were widely popular in the eighties and early nineties.Recent research considers them to be quite safe.

SARMs like ostarine work in different ways  from other groups of compounds. Based on animal studies, they work by binding selectively to the body’s androgen receptors. This property gives ostarine and other compounds an edge because they do not cause extreme effects and alterations to the chemical balance of the test subject.

MK-2866 Properties and Structure

The compound has a density of 1.4±0.1 g/cm3, boiling Point of 632.3±55.0 °C at 760 mmHg
and a Flash Point of 336.2±31.5 °C.

MK-2866 has molecular formula: C19H14F3N3O3, molecular weight: 389.32 and an exact mass of 389.098724.

Mechanism of Action

As earlier stated, ostarine is classified under a group of compounds called SARM (Selective Androgen Receptor Modulator). Compounds that fall under this group have high affinity to the androgen receptors, thus, ostarine binds itself preferably to receptors present in the bones and muscles. The compound simultaneously enhances anabolic activities such as protein synthesis and reduction in catabolic actions after binding to its target receptor. All these lead to growth and regeneration of muscle tissues and promotion of an increase in connective tissues. The end result is that MK2866 strengthens muscles, increases bone density and stimulates faster recovery.

MK-2866 Results

Ostarine is best known for its impact on mass and muscle strength. Reduction in muscle mass may lead to impairment of  physical functions which may limit the motion and movement range. Ostarine/MK-2866 compound can undo all these effects. SARMs increase lean mass muscle effectively.

This compound (MK-2866) can facilitate bone healing and growth of stronger muscles to aid regeneration. Animal tests have shown conclusive results that fractures, hairline cracks and other bone problems can heal quicker after administration of MK-2866.

This compound has the ability to aid in the functioning of the heart because it has a positive impact on muscle mass. Weakened muscles would have an adverse effect on the quintessential functioning of the heart.

Where can I find MK-2866 ostarine for sale?

You can buy MK-2866 at Loti labs in its liquid form. Ostarine and other SARMs for sale at Loti Labs meet the highest US quality standards by passing through testing by high power liquid chromatography (HPLC) and mass spectrometry.

References

Nagle, Mike (7 November 2007). “Merck flexes muscle with GTx deal”. Outsourcing Pharma.

Sheffield, Michael (April 4, 2014). “Steiner resigns from GTx”. Memphis Business Journal.

Zhang, Xuqing; Lanter, James C; Sui, Zhihua (8 June 2009). “Recent advances in the development of selective androgen receptor modulators.” Expert Opinion on Therapeutic Patents. 19 (9): 1239–1258. doi:10.1517/13543770902994397. PMID 19505196. The first quoted sentence is cited to Published PCT application WO2008127717